Target Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2 ...

NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis Pharmaceuticals Interim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a l ...

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – t ...

If the market's dramatic shifts this year leave you discombobulated, you're not alone. But, despite widespread overvaluation across a range of tech stocks, plenty of cheap blue-chip stocks are ready to offer the portfolio stability we're all desperately seeking. Amidst the current rally, we've seen stocks rise, plummet and rise again, driving investors toward small-caps, tech and growth stocks. While this has been profitable, it might not be the best long-term move. Cheap blue- chip stocks, on the other han ...

Have you assessed how the international operations of Jazz Pharmaceuticals (JAZZ) performed in the quarter ended March 2024? For this drugmaker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investo ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $2.68 per share in first-quarter 2024, missing the Zacks Consensus Estimate of $4.14. Earnings fell 32% year over year, primarily due to increased operating expenses incurred during the quarter.Total revenues in the reported quarter rose 1% year over year to $902 million, driven by higher oncology product sales, which were partially offset by lower neuroscience revenues. Per management, revenues were impacted by seasonal headwinds from payor reauthor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or 011-353-1-634-7800 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (St ...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Andrea Flynn – Vice President and Head-Investor Relations Bruce Cozadd – Chairman and Chief Executive Officer Renée Galá – President and Chief Operating Officer Rob Iannone – Executive Vice President and Global Head-R&D Phil Johnson – Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye – JPMorgan Jason Gerberry – Bank of America Marc Goodman – Leerink ...

Jazz Pharmaceuticals (JAZZ) reported $901.98 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1%. EPS of $2.68 for the same period compares to $3.95 a year ago.The reported revenue represents a surprise of -3.94% over the Zacks Consensus Estimate of $938.99 million. With the consensus EPS estimate being $4.14, the EPS surprise was -35.27%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

• Expanded field force to increase the breadth of IH prescribers 9,050 9,300 9,500 9,525 9,900 2,000 2,200 2,550 2,775 3,050 Narcolepsy IH 12,050 11,050 11,500 12,300 12,950 ACTIVE XYWAV PATIENTS1 1Q23 2Q23 3Q23 4Q23 1Q24 Sleep Franchise • Total 1Q24 sleep revenue of $430 2 million • Expect high-sodium AG royalty revenue to exceed $200M in 2024 Expect Xywav to Remain Oxybate of Choice • Revenue grew 14% YoY Narcolepsy • Benefits of reducing sodium intake and an individualized dosing regimen continue to reso ...